Metabolic
MOTS-c
Also known as: Mitochondrial ORF of the 12S rRNA type-c
Identity and specification
- CAS number
- 1627580-64-6
- Molecular formula
- C101H152N28O22S2
- Molar mass
- 2174.57 g/mol
Batch certificates on file
Figures below are copied from independent certificates prepared by ILS Laboratories, San Diego, CA. A figure describes one tested lot and nothing beyond it; the PDF holds the complete report and chromatogram.
Lot MS40-09 · MOTS-c 40 mgView certificate (PDF)
- Purity specification
- ≥ 99.0% (HPLC)
- Lot result
- 99.83% — Lot MS40-09, assayed 18 Aug 2026Average of all vials sampled in this lot: 99.54%
- Laboratory
- ILS Laboratories, San Diego, CA
- Method
- HPLC, identity by retention-time match to reference standard
- Certificate
- COA-2026-956996
- Labelled content
- 40 mg
- Net peptide content
- 42.21 mg
- Identity (HPLC-RTM)
- MOTS-c — confirmed
- Heavy metals (ICP-MS)
- As, Cd, Cr, Hg, Pb — not detected
- Sterility (PCR)
- No growth
- Endotoxin (USP <85>)
- 0.104 EU/mL
- Fentanyl screen
- Not detected
Published study designs
Study parameters below are reported as published. They describe what each study did, not guidance of any kind.
No study designs indexed yet.
Identification and structure
MOTS-c is a 16-residue peptide encoded by the mitochondrial 12S rRNA region rather than by nuclear DNA, one of a small group of mitochondrial-derived peptides. It is supplied as a lyophilised solid. Identity is confirmed by mass spectrometry and purity by reversed-phase HPLC with a stated method. Because the sequence is short and its commercial supply recent, batch-to-batch identity confirmation is a more meaningful documentation check than a purity percentage alone. Analytical values on this record are transcribed from supplier documentation.
Discovery and characterisation history
MOTS-c was described in 2015 by a research group studying short open reading frames within mitochondrial DNA, following earlier work on humanin. Its identification was significant conceptually because it supported the idea that the mitochondrial genome encodes signalling peptides that act beyond the organelle. The field is young: essentially the whole literature postdates 2015, and the number of independent groups working on it remains small.
Mechanisms examined in published work
Published work examines activation of AMP-activated protein kinase, effects on the folate-methionine cycle and on AICAR accumulation, regulation of glucose uptake in skeletal muscle preparations, and translocation to the nucleus under metabolic stress with reported effects on stress-response gene expression. Rodent studies examined insulin sensitivity, diet-induced obesity endpoints and exercise capacity. Human observational work has examined circulating peptide concentrations in relation to age and metabolic status.
Where the evidence is strong
Mitochondrial encoding of the peptide and its detectability in human plasma are established findings. AMPK activation in cell and rodent systems has been reported by more than one group. Association between lower circulating concentrations and older age or adverse metabolic status has been observed in more than one cohort, though association is not causation and the cohorts are small.
Independent confirmation that the peptide is translated and detectable, rather than being an artefact of sequence prediction, has come from more than one laboratory using mass-spectrometric detection in human samples. That is a meaningful baseline finding and should be distinguished from the functional claims built on top of it.
Where the evidence is thin or absent
There are no completed randomised controlled human trials of administered MOTS-c for any indication. Every interventional finding is from cell culture or rodent models, and the rodent studies use small groups with short durations. The literature is concentrated in a small number of related laboratories, so apparent consistency across papers overstates the degree of independent replication. Human data are observational and cross-sectional, which cannot distinguish cause from consequence: lower concentrations in metabolically unwell participants may be a marker rather than a driver. Pharmacokinetics of exogenously supplied peptide in humans are unstudied. This is an early-stage research subject and should be evaluated as one.
Handling, stability and storage
Store the lyophilised solid per the storage conditions on this record, protected from light and moisture, with the sealed vial equilibrated before opening. Humidity uptake and repeated freeze-thaw of reconstituted material are the principal handling risks. This section describes laboratory handling of the material as supplied and provides no preparation or administration procedure.
Because the commercial supply of this peptide is recent and the analytical reference standards are less widely distributed than for older sequences, comparing certificates between suppliers is harder and identity confirmation on each batch is correspondingly more important.
Referenced literature
Indexed citations with verified PMIDs appear below. See testing methodology for analytical methods and sourcing standards for batch documentation requirements. Related metabolic records are listed in the compound index.
Handling and storage
Handling conditions pending supplier documentation.
Published research
Evidence snapshot
No records indexed — no distribution to plot.
No literature is indexed for this compound on this site yet. Absence here is not evidence about the compound; it means nothing has been reviewed and published to this record.
This compound is supplied with per-lot certificates of analysis.
View supplier listing: MOTS-cHow to read this
These entries index what has been published, not what has been established. Findings in cell culture or animal models do not transfer to human outcomes, and a citation appearing here is not a claim that the compound does anything in a person. None of these materials are approved for human or veterinary use. Summaries describe what each publication reported; read the source before relying on any of it.
Common questions
What is the recorded identity of MOTS-c?
The reference record lists CAS number 1627580-64-6, molecular formula C101H152N28O22S2, molar mass 2174.57 g/mol. Identity is confirmed per batch by HPLC retention-time match and mass spectrometry on the certificate of analysis.
Is MOTS-c intended for human or veterinary use?
No. MOTS-c as catalogued here is a laboratory research material only. It is not a drug, food, or dietary supplement, and it is not for diagnostic or therapeutic use.
Related compounds
Tesamorelin
Research reference — 218949-48-5
Ipamorelin
Research reference — 170851-70-4
CJC-1295
Research reference — 863288-34-0
AOD-9604
Research reference — 221231-10-3
Tirzepatide
Research reference — 2023788-19-2
Retatrutide
Research reference — 2381089-83-2
This material is catalogued by our supply partner as a research-use-only item. Batch documentation is issued with each shipment.
Peptide calculator · Testing methodology · Sourcing standards · Compound index
Research use only
For laboratory research use only. Not for human or veterinary consumption. Not a drug, food, or dietary supplement. Not for diagnostic or therapeutic use. All materials referenced on this site are supplied to qualified laboratories and research institutions for in-vitro and analytical work.
